Cargando…
A Randomized, Double-Blind, Placebo-Controlled Investigation of Selenium Supplementation in Women at Elevated Risk for Breast Cancer: Lessons for Re-Emergent Interest in Selenium and Cancer
Damage to cellular macromolecules such as DNA and lipid, induced via reactive oxygen species, and indicators of cell proliferation potential such as insulin-like growth factor (IGF) metabolic status are intermediate biomarkers of breast cancer risk. Based on reports that selenium status can affect t...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9855926/ https://www.ncbi.nlm.nih.gov/pubmed/36672557 http://dx.doi.org/10.3390/biomedicines11010049 |
_version_ | 1784873495559143424 |
---|---|
author | Thompson, Henry J. Sedlacek, Scot M. Fitzgerald, Vanessa K. Wolfe, Pamela McGinley, John N. |
author_facet | Thompson, Henry J. Sedlacek, Scot M. Fitzgerald, Vanessa K. Wolfe, Pamela McGinley, John N. |
author_sort | Thompson, Henry J. |
collection | PubMed |
description | Damage to cellular macromolecules such as DNA and lipid, induced via reactive oxygen species, and indicators of cell proliferation potential such as insulin-like growth factor (IGF) metabolic status are intermediate biomarkers of breast cancer risk. Based on reports that selenium status can affect these markers, a randomized, placebo-controlled, double-blind experiment was conducted to investigate the potential of selenium supplementation to modulate breast cancer risk. Using a placebo tablet or a tablet containing 200 μg selenium provided as high-selenium yeast daily for one year, concentrations of the biomarkers in blood or urine were assessed at baseline and after 6 and 12 months of intervention. The selenium intervention used in this study is presumed to mediate its effect via the induction of glutathione peroxidase activity and the consequential impact of the active form of this protein on oxidative damage. We found no evidence to support this hypothesis or to indicate that systemic IGF metabolic status was affected. Critical knowledge gaps must be addressed for the resurgence of interest in selenium and cancer to garner clinical relevance. Those knowledge gaps include the identification of a specific, high-affinity selenium metabolite and the cellular target(s) to which it binds, and the demonstration that the cellular determinant that the selenium metabolite binds plays a critical role in the initiation, promotion, or progression of a specific type of cancer. |
format | Online Article Text |
id | pubmed-9855926 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-98559262023-01-21 A Randomized, Double-Blind, Placebo-Controlled Investigation of Selenium Supplementation in Women at Elevated Risk for Breast Cancer: Lessons for Re-Emergent Interest in Selenium and Cancer Thompson, Henry J. Sedlacek, Scot M. Fitzgerald, Vanessa K. Wolfe, Pamela McGinley, John N. Biomedicines Article Damage to cellular macromolecules such as DNA and lipid, induced via reactive oxygen species, and indicators of cell proliferation potential such as insulin-like growth factor (IGF) metabolic status are intermediate biomarkers of breast cancer risk. Based on reports that selenium status can affect these markers, a randomized, placebo-controlled, double-blind experiment was conducted to investigate the potential of selenium supplementation to modulate breast cancer risk. Using a placebo tablet or a tablet containing 200 μg selenium provided as high-selenium yeast daily for one year, concentrations of the biomarkers in blood or urine were assessed at baseline and after 6 and 12 months of intervention. The selenium intervention used in this study is presumed to mediate its effect via the induction of glutathione peroxidase activity and the consequential impact of the active form of this protein on oxidative damage. We found no evidence to support this hypothesis or to indicate that systemic IGF metabolic status was affected. Critical knowledge gaps must be addressed for the resurgence of interest in selenium and cancer to garner clinical relevance. Those knowledge gaps include the identification of a specific, high-affinity selenium metabolite and the cellular target(s) to which it binds, and the demonstration that the cellular determinant that the selenium metabolite binds plays a critical role in the initiation, promotion, or progression of a specific type of cancer. MDPI 2022-12-25 /pmc/articles/PMC9855926/ /pubmed/36672557 http://dx.doi.org/10.3390/biomedicines11010049 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Thompson, Henry J. Sedlacek, Scot M. Fitzgerald, Vanessa K. Wolfe, Pamela McGinley, John N. A Randomized, Double-Blind, Placebo-Controlled Investigation of Selenium Supplementation in Women at Elevated Risk for Breast Cancer: Lessons for Re-Emergent Interest in Selenium and Cancer |
title | A Randomized, Double-Blind, Placebo-Controlled Investigation of Selenium Supplementation in Women at Elevated Risk for Breast Cancer: Lessons for Re-Emergent Interest in Selenium and Cancer |
title_full | A Randomized, Double-Blind, Placebo-Controlled Investigation of Selenium Supplementation in Women at Elevated Risk for Breast Cancer: Lessons for Re-Emergent Interest in Selenium and Cancer |
title_fullStr | A Randomized, Double-Blind, Placebo-Controlled Investigation of Selenium Supplementation in Women at Elevated Risk for Breast Cancer: Lessons for Re-Emergent Interest in Selenium and Cancer |
title_full_unstemmed | A Randomized, Double-Blind, Placebo-Controlled Investigation of Selenium Supplementation in Women at Elevated Risk for Breast Cancer: Lessons for Re-Emergent Interest in Selenium and Cancer |
title_short | A Randomized, Double-Blind, Placebo-Controlled Investigation of Selenium Supplementation in Women at Elevated Risk for Breast Cancer: Lessons for Re-Emergent Interest in Selenium and Cancer |
title_sort | randomized, double-blind, placebo-controlled investigation of selenium supplementation in women at elevated risk for breast cancer: lessons for re-emergent interest in selenium and cancer |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9855926/ https://www.ncbi.nlm.nih.gov/pubmed/36672557 http://dx.doi.org/10.3390/biomedicines11010049 |
work_keys_str_mv | AT thompsonhenryj arandomizeddoubleblindplacebocontrolledinvestigationofseleniumsupplementationinwomenatelevatedriskforbreastcancerlessonsforreemergentinterestinseleniumandcancer AT sedlacekscotm arandomizeddoubleblindplacebocontrolledinvestigationofseleniumsupplementationinwomenatelevatedriskforbreastcancerlessonsforreemergentinterestinseleniumandcancer AT fitzgeraldvanessak arandomizeddoubleblindplacebocontrolledinvestigationofseleniumsupplementationinwomenatelevatedriskforbreastcancerlessonsforreemergentinterestinseleniumandcancer AT wolfepamela arandomizeddoubleblindplacebocontrolledinvestigationofseleniumsupplementationinwomenatelevatedriskforbreastcancerlessonsforreemergentinterestinseleniumandcancer AT mcginleyjohnn arandomizeddoubleblindplacebocontrolledinvestigationofseleniumsupplementationinwomenatelevatedriskforbreastcancerlessonsforreemergentinterestinseleniumandcancer AT thompsonhenryj randomizeddoubleblindplacebocontrolledinvestigationofseleniumsupplementationinwomenatelevatedriskforbreastcancerlessonsforreemergentinterestinseleniumandcancer AT sedlacekscotm randomizeddoubleblindplacebocontrolledinvestigationofseleniumsupplementationinwomenatelevatedriskforbreastcancerlessonsforreemergentinterestinseleniumandcancer AT fitzgeraldvanessak randomizeddoubleblindplacebocontrolledinvestigationofseleniumsupplementationinwomenatelevatedriskforbreastcancerlessonsforreemergentinterestinseleniumandcancer AT wolfepamela randomizeddoubleblindplacebocontrolledinvestigationofseleniumsupplementationinwomenatelevatedriskforbreastcancerlessonsforreemergentinterestinseleniumandcancer AT mcginleyjohnn randomizeddoubleblindplacebocontrolledinvestigationofseleniumsupplementationinwomenatelevatedriskforbreastcancerlessonsforreemergentinterestinseleniumandcancer |